NASDAQ:RVMD

Revolution Medicines Stock Insider Trading

Healthcare > Biotechnology

Buy RVMD

*Your capital is at risk

$155.99

+4.68 (+3.09%)

At Close: Jun 03, 2026

Revolution Medicines Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -56.46. In total, the insiders bought 1.73M and sold 485.44K RVMD shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-56.46
● Buy	1.73M shares
● Sell	485.44K shares
50% Buy Activity Weak Negative Correlation
Sell Signal Medium Confidence Apr 15, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -56.46. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 20, 2026 Buy	Common Stock	Sandler Alan B. Chief Development Officer	Officer	0 Value: $0
Mar 20, 2026 Buy	Stock Option (Right to Buy)	Sandler Alan B. Chief Development Officer	Officer	167 300 Value: $9.84M
Mar 20, 2026 Buy	Stock Option (Right to Buy)	Sandler Alan B. Chief Development Officer	Officer	11 700 Value: $1.19M
Mar 19, 2026 Sell	Common Stock S-Sale	Cislini Jeff General Counsel	Officer	1 163 Value: $113.3K
Mar 17, 2026 Sell	Common Stock S-Sale	Wang Xiaolin See Remarks	Officer	2 010 Value: $200.0K
Mar 17, 2026 Sell	Common Stock S-Sale	Cislini Jeff General Counsel	Officer	1 795 Value: $178.6K
Mar 17, 2026 Sell	Common Stock S-Sale	Anders Jack Chief Financial Officer	C-Suite Officer	2 753 Value: $273.9K
Mar 17, 2026 Sell	Common Stock S-Sale	Horn Margaret A Chief Operating Officer	C-Suite Officer	4 583 Value: $455.9K
Mar 17, 2026 Sell	Common Stock S-Sale	Goldsmith Mark A See Remarks	Officer	12 871 Value: $1.28M
Mar 17, 2026 Sell	Common Stock S-Sale	Kelsey Stephen Michael See Remarks	Officer	4 302 Value: $428.0K
Mar 17, 2026 Sell	Common Stock S-Sale	Wei Lin Chief Medical Officer	Officer	2 073 Value: $206.2K
Mar 04, 2026 Sell	Common Stock G-Gift	Anderson Elizabeth M Director	Director	15 000 Value: $0
Mar 04, 2026 Buy	Common Stock G-Gift	Anderson Elizabeth M Director	Director	15 000 Value: $1.52M
Mar 02, 2026 Sell	Common Stock S-Sale	Goldsmith Mark A See Remarks	Officer	800 Value: $81.6K
Mar 02, 2026 Sell	Common Stock S-Sale	Goldsmith Mark A See Remarks	Officer	2 100 Value: $213.4K
Mar 02, 2026 Sell	Common Stock S-Sale	Goldsmith Mark A See Remarks	Officer	1 700 Value: $172.5K
Mar 02, 2026 Sell	Common Stock S-Sale	Goldsmith Mark A See Remarks	Officer	600 Value: $60.1K
Mar 02, 2026 Sell	Common Stock S-Sale	Goldsmith Mark A See Remarks	Officer	400 Value: $40.0K
Mar 02, 2026 Sell	Common Stock S-Sale	Goldsmith Mark A See Remarks	Officer	100 Value: $10K
Mar 02, 2026 Sell	Common Stock S-Sale	Goldsmith Mark A See Remarks	Officer	100 Value: $10K
Mar 02, 2026 Sell	Common Stock S-Sale	Goldsmith Mark A See Remarks	Officer	851 Value: $87.0K
Mar 02, 2026 Sell	Common Stock S-Sale	Goldsmith Mark A See Remarks	Officer	21 329 Value: $2.17M
Mar 02, 2026 Sell	Common Stock S-Sale	Goldsmith Mark A See Remarks	Officer	3 620 Value: $364.7K
Mar 02, 2026 Buy	Common Stock M-Exempt	Goldsmith Mark A See Remarks	Officer	30 000 Value: $122.7K
Mar 02, 2026 Sell	Common Stock S-Sale	Goldsmith Mark A See Remarks	Officer	700 Value: $68.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT REVOLUTION MEDICINES INC.

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells...

Read Full Profile Here